SCI ADV: AAV gene therapy solves osteoarthritis and obesity problems
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Obesity-related inflammation and loss of muscle function play a key role in the development of osteoarthritis (OA), so treatment of muscle tissue may provide new ways to restore obesity-related metabolic and biomechanical dysfunctionFollistatin (FST), a protein that binds to myoglobin and activators, may have the potential to strengthen muscle formation while suppressing inflammationtherefore, the researchers hypothesized that adeno-related virus 9 (AAV9) delivery of FST enhances muscle formation and reduces metabolic inflammation and knee osteoarthritis in mice caused by a high-fat dietexperiments have shown that AAV-mediated FST delivery can reduce obesity-induced inflammatory fat factors and cytokines in systemic and joint sliding membrane fluidsRegardless of diet, mice treated with the FST gene were protected from post-traumatic OA and joint injury-induced bone reconstructionthese findings suggest that FST gene therapy can provide a multi-factor treatment for injury-induced OA and metabolic inflammation in obesity
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
